The urokinase plasminogen activator and its receptor

 

 Buy Article Permissions and Reprints

Summary

The urinary-type plasminogen activator, or uPA, controls matrix degradation through the conversion of plasminogen into plasmin and is regarded as the critical trigger for plasmin generation during cell migration and invasion, under physiological and pathological conditions (such as cancer metastasis).The proteolytic activity of uPA is responsible for the activation or release of several growth factors and modulates the cell survival/apoptosis ratio through the dynamic control of cell-matrix contacts. The urokinase receptor (uPAR), binding to the EGF-like domain of uPA, directs membrane-associated extracellular proteolysis and signals through transmembrane proteins, thus regulating cell migration, adhesion and cytoskeletal status. However, recent evidence highlights an intricate relationship linking the uPA/uPAR system to cell growth and apoptosis.

• References

• 1 Johnsen M, Lund LR, Romer J. et al Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation.. Curr Opin Cell Biol 1998; 10 (05) 667-71.
  CrossrefPubMedGoogle Scholar
• 2 Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator.. Nat Rev Mol Cell Biol 2002; 03 (12) 932-43.
  CrossrefPubMedGoogle Scholar
• 3 List K, Jensen ON, Bugge TH. et al Plasminogenindependent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.. Biochemistry 2000; 39: 508-15.
  CrossrefPubMedGoogle Scholar
• 4 Franco P, Iaccarino C, Chiaradonna F. et al Phosphorylation of pro-urokinase at Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adhesion and motility.. J Cell Biol 1997; 137: 779-91.
  CrossrefPubMedGoogle Scholar
• 5 Camani C, Gavin O, Bertossa C. et al Studies on the effect of fucosylated and non-fucosylated finger/ growth-factor constructs on the clearance of tissuetype plasminogen activator mediated by the low-density- lipoprotein-receptor-related protein.. Eur J Biochem 1998; 251: 804-11.
  CrossrefPubMedGoogle Scholar
• 6 Riccio A, Grimaldi G, Verde P. et al The human urokinase-plasminogen activator gene and its promoter.. Nucleic Acids Res 1985; 13 (08) 2759-71.
  CrossrefPubMedGoogle Scholar
• 7 Irigoyen JP, Munoz-Canoves P, Montero L. et al The plasminogen activator system: biology and regulation.. Cell Mol Life Sci 1999; 56 1舑2 104-32.
  CrossrefPubMedGoogle Scholar
• 8 Miralles F, Parra M, Caelles C. et al UV irradiation induces the murine urokinase-type plasminogen activator gene via the c-Jun N-terminal kinase signalling pathway: requirement of an AP1 enhancer element.. Mol Cell Biol 1998; 18 (08) 4537-47.
  CrossrefPubMedGoogle Scholar
• 9 Watabe T, Yoshida K, Shindoh M. et al The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor.. Int J Cancer 1998; 77 (01) 128-37.
  CrossrefPubMedGoogle Scholar
• 10 Han Q, Leng J, Bian D. et al Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells.. J Biol Chem 2002; 277 (50) 48379-85.
  CrossrefPubMedGoogle Scholar
• 11 Tran H, Maurer F, Nagamine Y. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2.. Mol Cell Biol 2003; 23 (20) 7177-88.
  CrossrefPubMedGoogle Scholar
• 12 Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.. J Cell Biol 1985; 100 (01) 86-92.
  CrossrefPubMedGoogle Scholar
• 13 Stoppelli MP, Corti A, Soffientini A. et al Differentiation- enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.. Proc Natl Acad Sci U S A 1985; 82 (15) 4939-43.
  CrossrefPubMedGoogle Scholar
• 14 Magdolen V, Rettenberger P, Koppitz M. et al Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.. Eur J Biochem 1996; 237 (03) 743-51.
  CrossrefPubMedGoogle Scholar
• 15 Simons K, Toomre D. Lipid rafts and signal transduction.. Nat Rev Mol Cell Biol 2000; 1 (01) 31-9.
  CrossrefPubMedGoogle Scholar
• 16 Cunningham O, Andolfo A, Santovito ML. et al Dimerization controls the lipid raft partitioning of uPAR/ CD87 and regulates its biological functions.. EMBO J 2003; 22 (22) 5994-6003.
  CrossrefPubMedGoogle Scholar
• 17 Carriero MV, Del Vecchio S, Capozzoli M. et al Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.. Cancer Res 1999; 59: 5307-14.
  PubMedGoogle Scholar
• 18 Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator.. Nat Rev Mol Cell Biol 2002; 3 (12) 932-43.
  CrossrefPubMedGoogle Scholar
• 19 Soravia E, Grebe A, De Luca P. et al A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene.. Blood 1995; 86 (02) 624-35.
  CrossrefPubMedGoogle Scholar
• 20 Zannetti A, Del Vecchio S, Carriero MV. et al Salvatore M. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma.. Cancer Res 2000; 60 (06) 1546-51.
  PubMedGoogle Scholar
• 21 Mazzieri R, Masiero L, Zanetta L. et al Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.. EMBO J 1997; 16: 2319-32.
  CrossrefPubMedGoogle Scholar
• 22 Carmeliet P, Moons L, Lijnen R. et al Urokinasegenerated plasmin activates matrix metalloproteinases during aneurysm formation.. Nat Genet 1997; 17 (04) 439-44.
  CrossrefPubMedGoogle Scholar
• 23 Behrendt N. The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling.. Biol Chem 2004; 385 (02) 103-36.
  CrossrefPubMedGoogle Scholar
• 24 Rossignol P, Ho-Tin-Noe B, Vranckx R. et al Protease nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells.. J Biol Chem 2004; 279 (11) 10346-56.
  CrossrefPubMedGoogle Scholar
• 25 Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation.. J Cell Sci 2003; 116 (Pt 2) 217-24.
  CrossrefPubMedGoogle Scholar
• 26 Lund LR, Romer J, Bugge TH. et al Functional overlap between two classes of matrix-degrading proteases in wound healing.. EMBO J 1999; 18: 4645-56.
  CrossrefPubMedGoogle Scholar
• 27 Zhang YW, Graveel C, Shinomiya N. et al Met decoys: will cancer take the bait?. Cancer Cell 2004; 6 (01) 5-6.
  CrossrefPubMedGoogle Scholar
• 28 Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor.. J Biol Chem 1991; 266 (19) 12752-8.
  CrossrefPubMedGoogle Scholar
• 29 Andolfo A, English WR, Resnati M. et al Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor.. Thromb Haemost 2002; 88 (02) 298-306.
  Article in Thieme ConnectPubMedGoogle Scholar
• 30 Sabapathy KT, Pepper MS, Kiefer F. et al Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system.. J Cell Biol 1997; 137 (04) 953-63.
  CrossrefPubMedGoogle Scholar
• 31 Devy L, Blacher S, Grignet-Debrus C. et al The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.. FASEB J 2002; 16 (02) 147-54.
  CrossrefPubMedGoogle Scholar
• 32 Zhou HM, Nichols A, Meda P. et al Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.. EMBO J 2000; 19 (17) 4817-26.
  CrossrefPubMedGoogle Scholar
• 33 Ikeo K, Takahashi K, Gojobori T. Different evolutionary histories of kringle and protease domains in serine proteases: a typical example of domain evolution.. J Mol Evol 1995; 40 (03) 331-6.
  CrossrefPubMedGoogle Scholar
• 34 Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules.. Cell 1985; 41 (03) 657-63.
  CrossrefPubMedGoogle Scholar
• 35 Kim KS, Hong YK, Joe YA. et al Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.. J Biol Chem 2003; 278 (13) 11449-56.
  CrossrefPubMedGoogle Scholar
• 36 Mukhina S, Stepanova V, Traktouev D. et al The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis.. J Biol Chem 2000; 275 (22) 16450-8.
  CrossrefPubMedGoogle Scholar
• 37 Liang OD, Chavakis T, Linder M. et al Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.. Biol Chem 2003; 384 (02) 229-36.
  CrossrefPubMedGoogle Scholar
• 38 Bdeir K, Kuo A, Sachais BS. et al The kringle stabilizes urokinase binding to the urokinase receptor.. Blood 2003; 102 (10) 3600-8.
  CrossrefPubMedGoogle Scholar
• 39 Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signalling for cell adhesion, migration and growth.. Curr Opin Cell Biol 2000; 12 (05) 613-20.
  CrossrefPubMedGoogle Scholar
• 40 Carriero MV, Del Vecchio S, Capozzoli M. et al Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.. Cancer Res 1999; 59: 5307-14.
  PubMedGoogle Scholar
• 41 Liu D, Aguirre Ghiso J, Estrada Y. et al EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.. Cancer Cell 2002; 1 (05) 445-57.
  CrossrefPubMedGoogle Scholar
• 42 Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication.. Curr Opin Cell Biol 2000; 12 (05) 621-8.
  CrossrefPubMedGoogle Scholar
• 43 Chiaradonna F, Fontana L, Iavarone C. et al Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence.. EMBO J 1999; 18 (11) 3013-23.
  CrossrefPubMedGoogle Scholar
• 44 Kirchheimer JC, Wojta J, Christ G. et al Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.. Proc Natl Acad Sci U S A 1989; 86: 5424-8.
  CrossrefPubMedGoogle Scholar
• 45 Fischer K, Lutz V, Wilhelm O. et al Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.. FEBS Lett 1998; 438 1–2 101-5.
  CrossrefPubMedGoogle Scholar
• 46 Kanse SM, Benzakour O, Kanthou C. et al Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders.. Arterioscler Thromb Vasc Biol 1997; 17: 2848-54.
  CrossrefPubMedGoogle Scholar
• 47 Koopman JL, Slomp J, de Bart AC. et al Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor.. J Biol Chem 1998; 273 (50) 33267-72.
  CrossrefPubMedGoogle Scholar
• 48 Rabbani SA, Mazar AP, Bernier SM. et al Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.. J Biol Chem 1992; 267 (20) 14151-6.
  CrossrefPubMedGoogle Scholar
• 49 Kook YH, Adamski J, Zelent A. et al The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.. EMBO 1994; 13 (17) 3983-91.
  CrossrefPubMedGoogle Scholar
• 50 Yu W, Kim J, Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy.. J Cell Biol 1997; 137 (03) 767-77.
  CrossrefPubMedGoogle Scholar
• 51 Aguirre-Ghiso JA, Liu D, Mignatti A. et al Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo.. Mol Biol Cell 2001; 12 (04) 863-79.
  CrossrefPubMedGoogle Scholar
• 52 Aguirre Ghiso JA. Inhibition of FAK signalling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo.. Oncogene 2002; 21 (16) 2513-24.
  CrossrefPubMedGoogle Scholar
• 53 Liu D, Aguirre Ghiso JA., Estrada Y. et al EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.. Cancer Cell 2002; 1: 445-457.
  CrossrefPubMedGoogle Scholar
• 54 Shapiro RL, Duquette JG, Roses DF. et al Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.. Cancer Res 1996; 56: 3597-604.
  PubMedGoogle Scholar
• 55 Gyetko MR, Sud S, Chen GH. et al Urokinasetype plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection.. J Immunol 2002; 168 (02) 801-9.
  CrossrefPubMedGoogle Scholar
• 56 Herbert JM, Lamarche I, Carmeliet P. Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor- BB for vascular smooth muscle cells.. J Biol Chem 1997; 272 (38) 23585-91.
  CrossrefPubMedGoogle Scholar
• 57 Suelves M, Lopez-Alemany R, Lluis F. et al Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo.. Blood 2002; 99 (08) 2835-44.
  CrossrefPubMedGoogle Scholar
• 58 Roselli HT, Su M, Washington K. et al Liver regeneration is transiently impaired in urokinase-deficient mice.. Am J Physiol 1998; 275 6Pt 1 G1472-9.
  PubMedGoogle Scholar
• 59 Gutierrez LS, Schulman A, Brito-Robinson T. et al Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.. Cancer Res 2000; 60 (20) 5839-47.
  PubMedGoogle Scholar
• 60 Yanamandra N, Konduri SD, Mohanam S. et al Downregulation of urokinase-type plasminogen activator receptor (uPAR) induces caspase-mediated cell death in human glioblastoma cells.. Clin Exp Metastasis 2000; 18 (07) 611-5.
  CrossrefPubMedGoogle Scholar
• 61 Krishnamoorthy B, Darnay B, Aggarwal B. et al Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligandinduced apoptosis.. Clin Cancer Res 2001; 7 (12) 4195-201.
  PubMedGoogle Scholar
• 62 Ma Z, Webb DJ, Jo M. et al Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells.. J Cell Sci 2001; 114 Pt 18 3387-96.
  CrossrefPubMedGoogle Scholar
• 63 Chandrasekar N, Mohanam S, Gujrati M. et al Downregulation of uPA inhibits migration and PI3k/Akt signalling in glioblastoma cells.. Oncogene 2003; 22 (03) 392-400.
  CrossrefPubMedGoogle Scholar
• 64 Cheng EH, Wei MC, Weiler S. et al BCL-2, BCLX( L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.. Mol Cell 2001; 8: 705-11.
  CrossrefPubMedGoogle Scholar
• 65 Wick W, Wagner S, Kerkau S. et al BCL-2 promotes migration and invasiveness of human glioma cells.. FEBS Lett 1998; 440 (03) 419-24.
  CrossrefPubMedGoogle Scholar
• 66 Trisciuoglio D, Iervolino A, Candiloro A. et al bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity.. J Biol Chem 2004; 279 (08) 6737-45.
  CrossrefPubMedGoogle Scholar
• 67 Barnhart BC, Legembre P, Pietras E. et al CD95 ligand induces motility and invasiveness of apoptosisresistant tumour cells.. EMBO J 2004; 23: 3175-85.
  CrossrefPubMedGoogle Scholar
• 68 Hanahan D, Weinberg RA. The hallmarks of cancer.. Cell 2000; 100 (01) 57-70.
  CrossrefPubMedGoogle Scholar
• 69 Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E. et al Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB.. Nature 1997; 385 6616 544-8.
  CrossrefPubMedGoogle Scholar
• 70 Frisch SM, Francis H. Disruption of epithelial cellmatrix interactions induces apoptosis.. J Cell Biol 1994; 124 (04) 619-26.
  CrossrefPubMedGoogle Scholar
• 71 Lund AH, Turner G, Trubetskoy A. et al Genomewide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice.. Nat Genet 2002; 32 (01) 160-5.
  CrossrefPubMedGoogle Scholar
• 72 Romer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy.. Curr Pharm Des 2004; 10 (19) 2359-76.
  CrossrefPubMedGoogle Scholar
• 73 Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.. Cancer Res 2002; 62 (08) 2390-7.
  PubMedGoogle Scholar
• 74 Sato S, Kopitz C, Schmalix WA. et al High-affinity urokinase-derived cyclic peptides inhibiting urokinase/ urokinase receptor-interaction: effects on tumor growth and spread.. FEBS Lett 2002; 528 1–3 212-6.
  CrossrefPubMedGoogle Scholar
• 75 Fabbrini MS, Carpani D, Bello-Rivero I. et al The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated.. FASEB J 1997; 11 (13) 1169-76.
  CrossrefPubMedGoogle Scholar
• 76 Adachi Y, Chandrasekar N, Kin Y. et al Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences.. Oncogene 2002; 21 (01) 87-95.
  CrossrefPubMedGoogle Scholar
• 77 Bu X, Khankaldyyan V, Gonzales-Gomez I. et al Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism.. Lab Invest 2004; 84 (06) 667-78.
  CrossrefPubMedGoogle Scholar
• 78 Pakneshan P, Szyf M, Farias-Eisner R. et al Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.. J Biol Chem 2004; 279 (30) 31735-44.
  CrossrefPubMedGoogle Scholar
• 79 Simon DI, Wei Y, Zhang L. et al Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function.. J Biol Chem 2000; 275: 10228-34.
  CrossrefPubMedGoogle Scholar
• 80 Franco P, Massa O, Garcia-Rocha M. et al Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist.. J Biol Chem 1998; 273: 27734-40.
  CrossrefPubMedGoogle Scholar
• 81 Guo Y, Higazi AA, Arakelian A. et al A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.. FASEB J 2000; 14: 1400-10.
  CrossrefPubMedGoogle Scholar
• 82 Mishima K, Mazar AP, Gown A. et al A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.. Proc Natl Acad Sci U S A 2000; 97: 8484-9.
  CrossrefPubMedGoogle Scholar